Assembly Biosciences (NASDAQ:ASMB) Issues Earnings Results, Beats Estimates By $2.99 EPS

Assembly Biosciences (NASDAQ:ASMB) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99, FiscalAI reports. Assembly Biosciences had a negative return on equity of 8.06% and a negative net margin of 8.47%.The business had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $7.42 million.

Assembly Biosciences Trading Up 3.5%

ASMB stock opened at $28.46 on Friday. The stock’s 50 day simple moving average is $28.16 and its 200 day simple moving average is $29.58. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $39.71. The stock has a market capitalization of $450.24 million, a PE ratio of -38.46 and a beta of 1.11.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. RA Capital Management L.P. bought a new position in shares of Assembly Biosciences during the third quarter valued at $26,122,000. Paradigm Biocapital Advisors LP bought a new position in Assembly Biosciences during the 4th quarter valued at about $22,625,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Assembly Biosciences during the 3rd quarter valued at about $6,425,000. Vanguard Group Inc. boosted its holdings in shares of Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after acquiring an additional 248,287 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Assembly Biosciences in the fourth quarter worth approximately $5,476,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ASMB shares. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.75.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.